2024-08-012025-07-312025-07-31false13535358AKOMA THERAPY LTD2025-09-0186900falseiso4217:GBPxbrli:pure135353582024-07-31135353582025-07-31135353582024-08-012025-07-31135353582023-07-31135353582024-07-31135353582023-08-012024-07-3113535358bus:SmallEntities2024-08-012025-07-3113535358bus:AuditExempt-NoAccountantsReport2024-08-012025-07-3113535358bus:AbridgedAccounts2024-08-012025-07-3113535358bus:PrivateLimitedCompanyLtd2024-08-012025-07-3113535358core:WithinOneYear2025-07-3113535358core:AfterOneYear2025-07-3113535358core:WithinOneYear2024-07-3113535358core:AfterOneYear2024-07-3113535358core:ShareCapital2025-07-3113535358core:SharePremium2025-07-3113535358core:RevaluationReserve2025-07-3113535358core:OtherReservesSubtotal2025-07-3113535358core:RetainedEarningsAccumulatedLosses2025-07-3113535358core:ShareCapital2024-07-3113535358core:SharePremium2024-07-3113535358core:RevaluationReserve2024-07-3113535358core:OtherReservesSubtotal2024-07-3113535358core:RetainedEarningsAccumulatedLosses2024-07-3113535358core:LandBuildings2025-07-3113535358core:PlantMachinery2025-07-3113535358core:Vehicles2025-07-3113535358core:FurnitureFittings2025-07-3113535358core:OfficeEquipment2025-07-3113535358core:NetGoodwill2025-07-3113535358core:IntangibleAssetsOtherThanGoodwill2025-07-3113535358core:ListedExchangeTraded2025-07-3113535358core:UnlistedNon-exchangeTraded2025-07-3113535358core:LandBuildings2024-07-3113535358core:PlantMachinery2024-07-3113535358core:Vehicles2024-07-3113535358core:FurnitureFittings2024-07-3113535358core:OfficeEquipment2024-07-3113535358core:NetGoodwill2024-07-3113535358core:IntangibleAssetsOtherThanGoodwill2024-07-3113535358core:ListedExchangeTraded2024-07-3113535358core:UnlistedNon-exchangeTraded2024-07-3113535358core:LandBuildings2024-08-012025-07-3113535358core:PlantMachinery2024-08-012025-07-3113535358core:Vehicles2024-08-012025-07-3113535358core:FurnitureFittings2024-08-012025-07-3113535358core:OfficeEquipment2024-08-012025-07-3113535358core:NetGoodwill2024-08-012025-07-3113535358core:IntangibleAssetsOtherThanGoodwill2024-08-012025-07-3113535358core:ListedExchangeTraded2024-08-012025-07-3113535358core:UnlistedNon-exchangeTraded2024-08-012025-07-3113535358core:MoreThanFiveYears2024-08-012025-07-3113535358core:Non-currentFinancialInstruments2025-07-3113535358core:Non-currentFinancialInstruments2024-07-3113535358dpl:CostSales2024-08-012025-07-3113535358dpl:DistributionCosts2024-08-012025-07-3113535358core:LandBuildings2024-08-012025-07-3113535358core:PlantMachinery2024-08-012025-07-3113535358core:Vehicles2024-08-012025-07-3113535358core:FurnitureFittings2024-08-012025-07-3113535358core:OfficeEquipment2024-08-012025-07-3113535358dpl:AdministrativeExpenses2024-08-012025-07-3113535358core:NetGoodwill2024-08-012025-07-3113535358core:IntangibleAssetsOtherThanGoodwill2024-08-012025-07-3113535358dpl:GroupUndertakings2024-08-012025-07-3113535358dpl:ParticipatingInterests2024-08-012025-07-3113535358dpl:GroupUndertakingscore:ListedExchangeTraded2024-08-012025-07-3113535358core:ListedExchangeTraded2024-08-012025-07-3113535358dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-08-012025-07-3113535358core:UnlistedNon-exchangeTraded2024-08-012025-07-3113535358dpl:CostSales2023-08-012024-07-3113535358dpl:DistributionCosts2023-08-012024-07-3113535358core:LandBuildings2023-08-012024-07-3113535358core:PlantMachinery2023-08-012024-07-3113535358core:Vehicles2023-08-012024-07-3113535358core:FurnitureFittings2023-08-012024-07-3113535358core:OfficeEquipment2023-08-012024-07-3113535358dpl:AdministrativeExpenses2023-08-012024-07-3113535358core:NetGoodwill2023-08-012024-07-3113535358core:IntangibleAssetsOtherThanGoodwill2023-08-012024-07-3113535358dpl:GroupUndertakings2023-08-012024-07-3113535358dpl:ParticipatingInterests2023-08-012024-07-3113535358dpl:GroupUndertakingscore:ListedExchangeTraded2023-08-012024-07-3113535358core:ListedExchangeTraded2023-08-012024-07-3113535358dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-08-012024-07-3113535358core:UnlistedNon-exchangeTraded2023-08-012024-07-3113535358core:NetGoodwill2025-07-3113535358core:IntangibleAssetsOtherThanGoodwill2025-07-3113535358core:LandBuildings2025-07-3113535358core:PlantMachinery2025-07-3113535358core:Vehicles2025-07-3113535358core:FurnitureFittings2025-07-3113535358core:OfficeEquipment2025-07-3113535358core:AfterOneYear2025-07-3113535358core:WithinOneYear2025-07-3113535358core:ListedExchangeTraded2025-07-3113535358core:UnlistedNon-exchangeTraded2025-07-3113535358core:ShareCapital2025-07-3113535358core:SharePremium2025-07-3113535358core:RevaluationReserve2025-07-3113535358core:OtherReservesSubtotal2025-07-3113535358core:RetainedEarningsAccumulatedLosses2025-07-3113535358core:NetGoodwill2024-07-3113535358core:IntangibleAssetsOtherThanGoodwill2024-07-3113535358core:LandBuildings2024-07-3113535358core:PlantMachinery2024-07-3113535358core:Vehicles2024-07-3113535358core:FurnitureFittings2024-07-3113535358core:OfficeEquipment2024-07-3113535358core:AfterOneYear2024-07-3113535358core:WithinOneYear2024-07-3113535358core:ListedExchangeTraded2024-07-3113535358core:UnlistedNon-exchangeTraded2024-07-3113535358core:ShareCapital2024-07-3113535358core:SharePremium2024-07-3113535358core:RevaluationReserve2024-07-3113535358core:OtherReservesSubtotal2024-07-3113535358core:RetainedEarningsAccumulatedLosses2024-07-3113535358core:NetGoodwill2023-07-3113535358core:IntangibleAssetsOtherThanGoodwill2023-07-3113535358core:LandBuildings2023-07-3113535358core:PlantMachinery2023-07-3113535358core:Vehicles2023-07-3113535358core:FurnitureFittings2023-07-3113535358core:OfficeEquipment2023-07-3113535358core:AfterOneYear2023-07-3113535358core:WithinOneYear2023-07-3113535358core:ListedExchangeTraded2023-07-3113535358core:UnlistedNon-exchangeTraded2023-07-3113535358core:ShareCapital2023-07-3113535358core:SharePremium2023-07-3113535358core:RevaluationReserve2023-07-3113535358core:OtherReservesSubtotal2023-07-3113535358core:RetainedEarningsAccumulatedLosses2023-07-3113535358core:AfterOneYear2024-08-012025-07-3113535358core:WithinOneYear2024-08-012025-07-3113535358core:Non-currentFinancialInstrumentscore:CostValuation2024-08-012025-07-3113535358core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-012025-07-3113535358core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-012025-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-012025-07-3113535358core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-012025-07-3113535358core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-012025-07-3113535358core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-012025-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-012025-07-3113535358core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-012025-07-3113535358core:Non-currentFinancialInstrumentscore:CostValuation2025-07-3113535358core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-07-3113535358core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-07-3113535358core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-07-3113535358core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-07-3113535358core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-07-3113535358core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-07-3113535358core:Non-currentFinancialInstrumentscore:CostValuation2024-07-3113535358core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-07-3113535358bus:Director12024-08-012025-07-31

AKOMA THERAPY LTD

Registered Number
13535358
(England and Wales)

Unaudited Financial Statements for the Year ended
31 July 2025

AKOMA THERAPY LTD
Company Information
for the year from 1 August 2024 to 31 July 2025

Director

Carl Barge

Registered Address

71-75 Shelton Street
Covent Garden
London
WC2H 9JQ

Registered Number

13535358 (England and Wales)
AKOMA THERAPY LTD
Balance Sheet as at
31 July 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets31,249-
1,249-
Current assets
Debtors42,4542,406
Cash at bank and on hand1,7622,671
4,2165,077
Creditors amounts falling due within one year5(4,278)(4,029)
Net current assets (liabilities)(62)1,048
Total assets less current liabilities1,1871,048
Net assets1,1871,048
Capital and reserves
Called up share capital100100
Profit and loss account1,087948
Shareholders' funds1,1871,048
The financial statements were approved and authorised for issue by the Director on 1 September 2025, and are signed on its behalf by:
Carl Barge
Director
Registered Company No. 13535358
AKOMA THERAPY LTD
Notes to the Financial Statements
for the year ended 31 July 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Office Equipment4
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
2.Average number of employees

20252024
Average number of employees during the year00
3.Tangible fixed assets

Total

£
Cost or valuation
Additions1,499
At 31 July 251,499
Depreciation and impairment
Charge for year250
At 31 July 25250
Net book value
At 31 July 251,249
At 31 July 24-
4.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables-2,406
Other debtors2,454-
Total2,4542,406
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
5.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables1,1411,024
Taxation and social security3,1373,005
Total4,2784,029
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.